Mitigation and management strategies for ocular events associated with tisotumab vedotin
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mitigation and management strategies for ocular events associated with tisotumab vedotin
Authors
Keywords
Antibody drug conjugate, Cervical cancer, Eye care, Ocular adverse events, Tissue factor, Tisotumab vedotin
Journal
GYNECOLOGIC ONCOLOGY
Volume 165, Issue 2, Pages 385-392
Publisher
Elsevier BV
Online
2022-03-09
DOI
10.1016/j.ygyno.2022.02.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
- (2021) Robert L Coleman et al. LANCET ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS
- (2019) Silvia Méndez-Martínez et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
- (2019) David S. Hong et al. CLINICAL CANCER RESEARCH
- Dry Eye
- (2018) Janine A. Clayton NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
- (2018) Ursula A Matulonis et al. CLINICAL CANCER RESEARCH
- Conjunctivitis Preferred Practice Pattern®
- (2018) Divya M. Varu et al. OPHTHALMOLOGY
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
- (2017) Hope S. Rugo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Conjunctivitis
- (2013) Amir A. Azari et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The relationship between tissue factor and cancer progression: insights from bench and bedside
- (2011) Y. W. van den Berg et al. BLOOD
- Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor
- (2011) Emiliano Cocco et al. BMC CANCER
- Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor
- (2011) Emiliano Cocco et al. CLINICAL & EXPERIMENTAL METASTASIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now